mAb104 + monomethyl auristatin E

**mAb104 + monomethyl auristatin E** is an experimental antibody-drug conjugate (ADC) comprising the monoclonal antibody mAb104 linked to the synthetic antimitotic agent monomethyl auristatin E (MMAE)[1][4][7]. mAb104 targets a conformationally exposed epitope on HER2 (human epidermal growth factor receptor 2), showing efficacy in HER2-overexpressing cancer xenograft models[3]. MMAE inhibits cell division by blocking tubulin polymerisation and is used as a cytotoxic payload in ADCs for targeted cancer therapy[1][4]. Upon intravenous administration, mAb104 binds to HER2 on cancer cells, is internalized, and MMAE is released (typically via a protease-cleavable linker such as MC-VC-PABC)[4][5]; free MMAE disrupts microtubules, leading to apoptosis. Such ADCs exploit the targeting specificity of monoclonal antibodies and the potency of MMAE to achieve cancer cell death while limiting systemic toxicity[4][6].

Other names

mAb104-MMAEmAb-104-MMAEmAb 104-MMAEmAb104 antibody–drug conjugatemAb104 vedotin (if the linker is vedotin)antibody-drug conjugate of mAb104 and MMAE